Scarica l'app Stockscreener
6.12
1.83%
0.11
Precedente Chiudi:
$6.01
Aprire:
$5.82
Volume 24 ore:
51,555
Relative Volume:
1.08
Capitalizzazione di mercato:
$175.15M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-5.85%
1M Prestazione:
+82.69%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$5.80
$6.20
Intervallo di 1 settimana:
$5.50
$6.55
Portata 52W:
$2.33
$6.76
Insight Molecular Diagnostics Inc Stock (IMDX) Company Profile
Nome
Insight Molecular Diagnostics Inc
Settore
Industria
Telefono
949-409-7600
Indirizzo
2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE
Confronta IMDX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMDX
Insight Molecular Diagnostics Inc
|
6.12 | 172.00M | 0 | 0 | 0 | 0.00 |
|
TMO
Thermo Fisher Scientific Inc
|
564.88 | 213.17B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
214.06 | 152.13B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
722.94 | 50.36B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
144.69 | 41.49B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
213.88 | 36.86B | 15.90B | 1.28B | 2.21B | 7.2842 |
Insight Molecular Diagnostics Inc Stock (IMDX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-28 | Iniziato | Lake Street | Buy |
| 2022-05-24 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2022-03-14 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2022-01-07 | Iniziato | Stephens | Overweight |
| 2022-01-06 | Ripresa | Piper Sandler | Overweight |
| 2021-03-17 | Ripresa | Needham | Buy |
| 2021-01-07 | Aggiornamento | The Benchmark Company | Speculative Buy → Buy |
| 2020-12-16 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-11-30 | Iniziato | BTIG Research | Buy |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2020-07-30 | Reiterato | The Benchmark Company | Speculative Buy |
| 2020-07-01 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-06-30 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2020-06-02 | Iniziato | Needham | Buy |
| 2019-02-13 | Iniziato | Piper Jaffray | Overweight |
| 2019-01-29 | Aggiornamento | Janney | Neutral → Buy |
| 2018-12-19 | Ripresa | Lake Street | Buy |
Mostra tutto
Insight Molecular Diagnostics Inc Borsa (IMDX) Ultime notizie
iMDx (NASDAQ: IMDX) schedules Q3 results for Nov 10, to attend Stephens conference - Stock Titan
What MACD trends signal for Insight Molecular Diagnostics Inc. (7OC0) stockEarnings Growth Report & Stepwise Entry/Exit Trade Alerts - newser.com
Is Insight Molecular Diagnostics Inc. (7OC0) stock a buy for dividend portfoliosWeekly Loss Report & Safe Capital Growth Tips - newser.com
Will Insight Molecular Diagnostics Inc. (7OC0) stock boost dividends furtherPortfolio Risk Report & Weekly High Potential Stock Alerts - newser.com
U.S., Europe, and Asia Pacific Molecular Diagnostics Market - openPR.com
Is Insight Molecular Diagnostics Inc. (7OC0) stock included in top ETFs2025 EndofYear Setup & Daily Growth Stock Investment Tips - newser.com
Analysts Offer Insights on Healthcare Companies: Align Tech (ALGN), TransMedics Group (TMDX) and Opko Health (OPK) - The Globe and Mail
Insight Molecular Diagnostics Advances Kidney Transplant Monitoring with New Study - TipRanks
Is Insight Molecular Diagnostics Inc. (7OC0) stock dividend growth reliablePortfolio Update Report & Weekly Setup with High ROI Potential - newser.com
On the Move: Oct. 21, 2025 - Nashville Post
BillionToOne IPO (BLLN.US): Unique Financial Profile For Molecular Diagnostics Company, Strong Buy - Smartkarma
US Market Wrap: What earnings margins imply for Insight Molecular Diagnostics Inc. (7OC0) stockWeekly Investment Summary & Technical Buy Zone Confirmation - Trung tâm Dự báo KTTV quốc gia
What earnings margins imply for Insight Molecular Diagnostics Inc. (7OC0) stock2025 Bull vs Bear & Comprehensive Market Scan Insights - Trung tâm Dự báo KTTV quốc gia
Returns Recap: Will Insight Molecular Diagnostics Inc. (7OC0) stock maintain strong growthWeekly Risk Report & Consistent Profit Trade Alerts - Trung tâm Dự báo KTTV quốc gia
Insight Molecular Diagnostics names Steven Tahmooressi as VP, marketing - Medical Buyer
Insight Molecular Diagnostics appoints Steven Tahmooressi as VP of Marketing - Investing.com Nigeria
Imdx welcomes new VP Marketing to prepare for commercial transplant assay launch - MarketScreener
iMDx Welcomes New VP Marketing to Prepare for Commercial Transplant Assay Launch - GlobeNewswire
GraftAssureDx kit launching 2026: iMDx hires Steven Tahmooressi as VP Marketing to lead global rollout - Stock Titan
Will Insight Molecular Diagnostics Inc. (7OC0) stock attract long term capital inflowsQuarterly Profit Report & Accurate Technical Buy Alerts - newser.com
Bullish Insight Molecular Diagnostics Insiders Rewarded As Their Investment Rises To US$4.85m - simplywall.st
Insight Molecular Diagnostics Inc.'s (NASDAQ:IMDX) large hedge funds owners must be happy as stock continues to impress, up 12% over the past week - Yahoo Finance
iMDx Reports Kidney Transplant Patient Achieved ‘Immune Reset’ with Novel Therapy and GraftAssure Monitoring - Sahm
Insight Molecular Diagnostics stock rises after transplant study publication - Investing.com
Insight Molecular Says GraftAssure Assay Helped Avoid Overtreatment in Kidney Transplant Patient - MarketScreener
IMDX's GraftAssure Assay Shows Promise in Kidney Transplant Moni - GuruFocus
GraftAssure test helps monitor kidney transplant patient during cancer therapy - Investing.com
Insight Molecular Diagnostics Inc Azioni (IMDX) Dati Finanziari
Non sono disponibili dati finanziari per Insight Molecular Diagnostics Inc (IMDX). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
1.64%
1.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):